Supply and Market Dynamics; Medicine Quality

Expanding the scope beyond COVID-19 to assess the production and distribution capacity for medicines and vaccines for infectious diseases of epidemic and pandemic potential, including AMR, to inform countries and international agencies and ensure an adequate supply of effective interventions.

Conducting market dynamics analyses and interventions to scale up production.

Monitoring and analyzing medicine quality reports during future epidemic or pandemic responses to facilitate timely dissemination of alerts.


Selected and recommended by the working group

Browse all resources selected by the coalition’s topic-specific groups

If you would like to submit a query to the Supply and Market Dynamics; Medicine Quality working group, please send us an email.

Submit a query

Working group members

Working Group Member

Pascale Boulet joined DNDi in November 2008 as Intellectual Property & Policy Advisor and acted as Head of Policy Affairs in 2012-2013. In 2017, Pascale became Intellectual Property & Access Leader, with the Business Development team. Pascale is a lawyer with 20 years of experience in intellectual property laws and policies, with a particular focus on pharmaceuticals. Prior to joining DNDi, Pascale acted as senior legal advisor of MSF Access Campaign and technical officer with WHO Medicines Department. Besides her part-time work at DNDi, Ms Boulet works as an independent consultant with various public health organizations. Pascale earned a Master in International Economic Law from the University of Panthéon-Sorbonne in Paris, and a Certificate in Public Health and Primary Health Care in Developing Countries from the University of Medicine of Montpellier, France.

Working Group Member

Dr Céline Caillet joined IDDO as Scientific Coordinator of the Medicine Quality Research Group in 2015, was appointed Research Scientist in 2016 and promoted as Deputy Head of the Medicine Quality Research Group in 2020. Céline is a pharmacist and former resident of the Hospital of Toulouse. She has taken part in several research projects on drug safety at the Center of Pharmacovigilance, Laboratory of Medical and Clinical Pharmacology of Toulouse, France. Following her MSc in Epidemiology and Public Health in Bordeaux, France, Céline completed her PhD in drug safety in Laos. During her PhD, Céline also taught pharmacology in the Department of Pharmacy at the University of Health Sciences, Vientiane. She is particularly interested in the epidemiology of substandard and falsified medicines and testing the performances of screening technologies for early detection of substandard and falsified medicines.

Working Group Member

Michelle Childs joined DNDi in April 2016 as Head of Policy Advocacy. Ms Childs has an extensive experience in proposing and advocating for solutions to access and innovation barriers faced by developing countries and health providers. She has helped to develop several proposals on innovation using open knowledge principles for Chagas disease, TB and was a co-author of the original proposal for the creation of a patent pool for HIV medicines by Unitaid. Prior to that, Ms Childs was an expert adviser for the WHO to help further develop four open knowledge demonstration projects from India, Brazil, South Africa and Thailand. Until March 2013 Michelle was Director of Policy Advocacy at Médecins Sans Frontières Access Campaign leading a multidisciplinary and multinational team. She has worked for leading consumer, health and knowledge rights organizations and public authorities including KEI, Which? and the Hong Kong and UK telecom regulators, and as member of a number of NGO and public advisory boards including the four person advisory board of the UK competition authority. She started her career as a commercial litigation lawyer in a City of London law firm.

Working Group Member

I am a Consultant Public Health physician and an expert in Pharmacovigilance and Pharmacoepidemiology with specialization in Medicines Risk identification and quantification. A fellow of the National Postgraduate Medical College of Nigeria-Faculty of Public Health and Community Medicine and also a Member of the West Africa College of Physicians-Faculty of Community Health. I obtained her Master’s degree in Pharmacovigilance and Pharmacoepidemiology from Eu2P – Universite de Bordeaux with specialization from Erasmus Medical Center; Master’s in Public Health as well as Medicine and Surgery degree from the University of Lagos Nigeria.
I am currently the Co-Chair West Africa for International Society of Pharmacoepidemiology Africa Chapter (ISPE-Africa).

I have over 12 years of experience working closely with diverse stakeholders from the community, government institutions, bilateral/multilateral organizations in the field of public health with an excellent understanding of the Health system and its socio-cultural linkages.

I am passionate about research. I have expertise in Epidemiology and Control of Communicable and non-communicable diseases, Reproductive health, Primary Health, Global Health, Health Management and policy. I have training and experience in Implementation research and Infection prevention and control.
I have contributed remarkably in the development of Pharmacovigilance and its systems in Nigeria and especially Pharmacovigilance in public health programmes.

I have managed several projects with local and International partners and have been a lead investigators several USAID-funded projects in Nigeria. My research outcome in uterotoincs in Nigeria is contributing to improvements in maternal healthcare in Nigeria.

I have presented, co-chaired committees, symposia, workshops and panel discussions at local and international conferences conferences and scientific meetings.

I volunteer as an Abstract mentor for the International AIDS Society(IAS), review abstracts for IAS, International Society of Pharmacoepidemiology(ISPE) and African Society of Pharmacovigilance(ASOP) scientific meetings and other scientific conferences.

I am a member of IAS,ASOP, ISOP, ISPE and APHPN, NSIC, Infection Control Africa Network (ICAN) and global alliance for Quality-assured Medical products and Global Health.

Working Group Co-Chair

Andrew Farlow is head of global public health initiatives, Oxford in Berlin (, where he convenes the COVID-19 Science and Policy Forum, bringing together scientists, policymakers, and the public for open discussion and consensus building, and is engaged with colleagues in creating a new Berlin Open Science Centre with a strong focus on planetary and human health. With nearly 20 years experience researching and advising on the development, deployment, and financing of vaccines and medicines (TB, malaria, HIV, shingles, chickenpox, dengue, and pandemic influenza, etc.), he has advised a wide range of public- and private-sector organizations (WHO, UNDP, Stop TB, Aeras/BMGF, JCVI, etc.). He is Teaching Fellow of the Nuffield Department of Medicine, University of Oxford, for its MSc in International Health & Tropical Medicine, and a Senior Fellow, Oxford Martin School, where he was Co-PI on its Vaccine Design Institute. He is Visiting Professor, Oswaldo Cruz Foundation – FIOCRUZ, Brazil, and working with the Institute of Drugs Technology — Farmanguinhos, Royal Botanic Gardens, Kew, Oxford, and a range of global collaborators on a new Global Partnership for Biodiversity, Medicine, and Health to sustainably develop new affordable medicines based on natural molecules, especially from plants, fungi, and algae, while protecting biodiversity.

Working Group Member

Gamal is a senior supply chain professional and a pharmacist. He graduated from Khartoum University with a degree in Pharmacy and obtained a PG diploma in health economics.  Gamal holds a master’s degree (MSc) in Pharmaceutical Services and Medicines Control with distinction from the University of Bradford, UK and a PhD in Health Economics with a focus on Accessibility to Medicines and Primary Health Care by the Nottingham Trent University, UK.

He has over 20 years of experience working in pharmaceuticals supply management in Sudan. From1993 to 2019 he worked as a manager of the Revolving Drug Fund in Khartoum state, led the Federal Directorate of Pharmacy as a manager of the Pharmaceutical Services and Planning Department, and worked as Director for the Public Health Institute.

In November 2007, Gamal was appointed Secretary General of the National Medicines & Poisons Board, the Medicine Regulatory Authority of Sudan and later became the Director General of the National Medical Supplies Fund (NMSF) from 5th of September 2010 to 1st April 2019. The NMSF is the national centre for procurement, storage and distribution of medical supplies in Sudan.

Gamal has strong expertise in various areas of pharmaceutical management, including Pharmaceutical Policy, Medical Supplies and Medicine regulations, among others. He was the pioneer and founder of the Post-Graduate fellowship in managing pharmaceutical services in Sudan and the National Medical Specialization Board.  He also founded the autonomous pharmaceutical regulatory authority in 2009 and led the Continuous Pharmaceutical Professional Development Programme that was established by the Sudanese Pharmacists Union and the government of Sudan.

Working Group Co-Chair

Mr. Paul S. Lotay is a Medical Anthropologist and Public Health Specialist with over 10 years of experience in health systems strengthening, supply chain management and health policy. Mr. Lotay has worked in various organizations at national, regional, and international levels providing technical information to different projects. With extensive knowledge of the pharma trade standards and experience in business management, Mr. Lotay focuses his passion on humanitarian endeavors by tackling supply and quality challenges, thus ensuring universal access to life-saving health commodities. He is currently the CEO of CHMP with the mission to sustain availability of high-quality medicines and essential commodities to global humanitarian programs.

Working Group Member

An accomplished pharmaceutical research and global health professional with extensive experience in reputable pharmaceutical companies and global health organizations. Skilled in directing global health programs to develop pharmaceutical policies, strengthen health systems and advocate for increased access to affordable quality assured medicines. Having led multi-million-dollar capacity building programs for USAID as program director and United States Pharmacopeia as vice president, Global Public health, and with firm background in pharmaceutical development, Dr Lukulay is currently the president of Technology Solutions for Global Health. Dr Lukulay has authored over 24 publications in reputable peer-review journals and is a frequent speaker at national and international conferences on health systems strengthening, pharmaceutical policy, quality control and quality assurance systems for medicines.He is a member of the American Chemical Society, a member of the board of directors for the Professional Science Masters (PSM) program for major Universities in the United States and chairman of the advisory board for Boston University’s PharmaChk Technology detection of poor-quality medicines and member of the International Pharmaceutical Federation (FIP) Expert group on Substandard and Falsified Medicines. Patrick received a B.S degree (Hons) from the University of Sierra Leone, an M.S. degree in Analytical Chemistry from the University of Aberdeen in Scotland and a Ph.D. in Analytical Chemistry from Michigan State University.Patrick has received several awards including the distinguished Alumnus award by Michigan State University.

Working Group Member

Jorge Magalhães completed his postdoctoral at Université de Provence Aix-Marseille (Institut de Recherche en Sciences de l’Information et de la Communication), France. Research was in Competitive Intelligence Survey for public health, using data and tools to collaborate, understand and facilitate attention to Health Sector, i.e; neglected tropical diseases. Plus Public Health at FIOCRUZ/Farmanguinhos in the Centre for Technological Innovation and General Coordinator Researcher Group Management and Prospecting in Health at FIOCRUZ. He has experience in Management and Technological Innovation, working mainly on: Knowledgement Management, Technological Trends, Big Data in Health, Open Data, Web 2.0, Patents for Pharmaceuticals, Pharmochemical and Global Health, One Health, and Public Health.

Working Group Member

Infectious disease doctor conducting research concentrating on answering questions about the epidemiology, impact and detection of substandard and falsified medicines. Head of Medicine Quality Research Group, Centre of Tropical Medicine & Global Health, University of Oxford. Director of Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao PDR 1999-2019

Working Group Member

Eurek Ranjit is based in Nepal where he works as a pharmacist and pharmacologist and is a lecturer of Pharmacology at Kathmandu Medical College. He is also a Board Member of Nepal Pharmacy Council, which provides licensure for pharmacists and pharmacists. He is also Section Vice President of International Pharmaceutical Federation (FIP).Eurek completed his Bachelor of Pharmacy (First Class First) obtaining highest GPA and Gold Medal from University of Karachi, Pakistan and went on to complete an MSc (Pharmacy Services and Medicines Control) and an M Phil (Pharmacology) in the United Kingdom.He previously worked as a hospital pharmacist at Patan Hospital, Nepal, and also held the position of Secretary of the Infection Control Committee and Drug and Therapeutics Committee. Eurek has also authored a number of papers in scientific journals.

Working Group Member

Raffaella Ravinetto holds a Pharmacy Master Degree, a Postgraduate Diploma in Tropical Medical Biology from the Antwerp Institute of Tropical Medicine (ITM), and a PhD in Biomedical Sciences from KU Leuven. After being a clinical researcher in the private pharmaceutical sector, she worked in humanitarian programs in the Balkans and Africa. In 2002, she joined Médecins Sans Frontières (MSF), where she followed various dossiers on access to/quality of essential medicines, while performing several field assessments in Africa and Latin America. Since 2006 to 2016, she was the head of the Clinical Trials Unit at ITM, as well as the coordinator of the Switching the Poles Clinical Research Network and the scientific coordinator of QUAMED, a network that promotes evidence-based strategies for universal access to quality-ensured medicines. She is currently a senior researcher at the ITM Public Health Department, in charge of a portfolio of research, networking and advocacy on medicines in low- and middle-income countries, and of a North-South network on research standards and ethics in low- and middle-income countries. She is a member if the ITM Institutional Review Board. She was president of the Italian branch of MSF (2007-2011). She’s the chairperson of MSF Ethics Review Board, and an ethical advisor to some EU-funded research projects.

Working Group Member
Working Group Member

Kerlijn Van Assche works in the Medicine Quality Research Group of the Infectious Diseases Data Observatory (IDDO) & Mahidol Oxford Research Unit (MORU). Initially, she was trained as a hospital pharmacist and later obtained a master’s in International Health at Charité’s Institute of Tropical Medicine and International Health in Germany.Previously, she was involved in research with the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, on data of QUAMED, a North-South Network that promotes universal access to quality-ensured medicines.Before joining the Medicine Quality Research Group, Kerlijn worked as a quality assurance pharmacist with Médecins Sans Frontières (MSF) ensuring the use of quality medicines and medical devices in their projects across the world.

Working Group Member

Ed Vreeke’s experience is related to essential generic medicines and medical supplies in the following fields: procurement and supply systems organisation, management, monitoring and evaluation, general management and organisation of Central Medical Stores, strategic and policy issues, business plan development, transitioning from government to independent organisation, development, organisation and management of tender processes, conception of revolving medicine funds, performance based financing systems, and costing analysis.

We are looking for dedicated individuals and institutions who are eager to contribute their expertise and commitment to fast-track research in infectious diseases with potential for epidemics and pandemics, as well as antimicrobial resistance (AMR), specific to low-resource settings.